Table 1.
Patient, tumor, and treatment characteristics
| Variables | EPclin Low risk (n = 154) |
EPclin High risk (n = 53) |
p value | ||
|---|---|---|---|---|---|
| patients, n | % | patients, n | % | ||
| Age, years | |||||
| <60 ≥60 |
124 30 |
(80.5) (19.5) |
45 8 |
(84.9) (15.1) |
0.550 |
|
| |||||
| Pathology | |||||
| IDC ILC Others |
132 14 8 |
(85.7) (9.1) (5.2) |
43 4 6 |
(81.1) (7.5) (11.3) |
0.323 |
|
| |||||
| Pathological T stage | |||||
| T1a T1b T1c T2 Tumor size* |
6 29 107 12 1.3 (0.1–3.4) |
(3.9) (18.8) (69.5) (7.8) |
0 3 31 19 1.7 (0.6–4.5) |
(0.0) (5.7) (58.5) (35.8) |
<0.001 <0.001 |
|
| |||||
| Pathological N stage | |||||
| N0 N1 |
146 8 |
(94.8) (5.2) |
45 8 |
(84.9) (15.1) |
0.033 |
|
| |||||
| Histologic grade | |||||
| I II III |
59 92 3 |
(38.3) (59.7) (1.9) |
9 31 13 |
(17.0) (58.5) (24.5) |
<0.001 |
|
| |||||
| Lymphovascular invasion | |||||
| Absent Present Unknown |
136 18 0 |
(88.3) (11.7) (0.0) |
43 9 1 |
(81.1) (17.0) (1.9) |
0.159 |
|
| |||||
| Resection margin | |||||
| Negative (≥1 mm) Positive Close (<1 mm) |
129 5 20 |
(83.8) (3.2) (13.0) |
42 3 8 |
(79.2) (5.7) (15.1) |
0.663 |
|
| |||||
| ER status | |||||
| Negative Positive |
0 154 |
(0.0) (100.0) |
0 53 |
(0.0) (100.0) |
|
|
| |||||
| PR status | |||||
| Negative Positive |
4 150 |
(2.6) (97.4) |
5 48 |
(9.4) (90.6) |
0.050 |
|
| |||||
| Type of surgery | |||||
| Breast conservation Mastectomy |
153 1 |
(99.4) (0.6) |
52 1 |
(98.1) (1.9) |
0.447 |
|
| |||||
| Chemotherapy | |||||
| No Yes |
153 1 |
(99.4) (0.6) |
10 43 |
(18.9) (81.1) |
<0.001 |
|
| |||||
| Endocrine therapy | |||||
| Tamoxifen only AI only Tamoxifen/AI Other (GnRH agonists) |
79 67 5 3 |
(51.3) (43.5) (3.2) (1.9) |
24 23 1 5 |
(45.3) (43.4) (1.9) (9.4) |
0.118 |
|
| |||||
| Regional nodal irradiation | |||||
| Breast or CW only SCL IMN SCL + IMN EPclin score* |
145 3 6 0 2.7 (1.0–3.3) |
(94.2) (1.9) (3.9) (0.0) |
49 2 1 1 3.8 (3.3–5.1) |
(92.5) (3.8) (1.9) (1.9) |
0.298 <0.001 |
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; AI, aromatase inhibitor; GnRH, gonadotropin-releasing hormone; CW, chest wall; SCL, supraclavicular node; IMN, internal mammary node.
*
Median (range).